Inauguration of Institute of Precision Medicine (IPM) and Institute of Biopharmaceutical Sciences (IBPS)
National Sun Yat-sen University (NSYSU) celebrates the inauguration of the Institute of Precision Medicine (IPM) and the Institute of Biopharmaceutical Sciences (IBPS), which will start recruiting students for the academic year 2020-2021. NSYSU President Ying-Yao Cheng said that with the global challenge of novel coronavirus outbreaks, these two institutes will focus on emerging human diseases, including new pathogen infections, metabolic disorders, cancer...etc. Achievements associated with these studies will provide strong supports to meet the urgent need of the society. The IPM will strive to develop personalized treatments and integrate treatment technologies suggested by artificial intelligence (AI) analyses. As for new drugs/treatments for clinical applications, the IBPS will focus on the development of key platforms/technologies for next-generation medications. The establishment of these two institutes is an important step for NSYSU to move forward towards advanced medicine which can be integrated into medical education at the University.
Facing the challenge of the novel coronavirus outbreaks, Professor Jim Jinn-Chyuan Sheu, Chair of the IBPS, pointed out that the novel coronavirus (COVID-19) is a newly defined virus that belongs to the Coronaviridae family. Similar to SARS-CoV and MERS-CoV, COVID-19 causes severe breathing difficulties in humans, which may be even lethal. In the near future, the IBPS will develop new antibody drugs, vaccines and novel phytochemicals against this devastating disease. At the same time, IBPS will cultivate professionals and researchers in the field of biopharmacy, finding new ways to treat severe diseases. Together with the faculty at Institute of Biomedical Sciences (IBMS), IBPS will conduct research on molecular mechanisms involved in viral infections and pathogenesis, providing strategies to block viral entry or to suppress virus replication in the infected cells. Through those studies, NSYSU will be able to establish a high throughput screening platform for new drug development against COVID-19.
According to the clinical statistics provided by the Chinese government and cited by Taiwan Centers for Disease Control, the median age of COVID-19-infected patients is about 49 years old and 73% of them are male. Professor Yow-Ling Shiue, Chair of the IPM, said that in the future, the Institute will do research to clarify the relationship between personal genomics and disease progression, and to understand why some infected patients show mild or even undetectable symptoms but some could be in very severe conditions. This study may help us to ensure no pitfalls in epidemic prevention. The IPM will cultivate interdisciplinary researchers with special focus on precision medicine to work on disease prediction, prevention and personalized treatments that can lead to biomedical innovation. By integrating the data of genetic signatures, lifestyles, environmental risk factors and health history, AI management and deep-learning technologies will enable us to design novel strategies in developing new diagnostic methods, drug delivery, systems and gene therapy for clinical practice.
In the future, these two institutes will integrate academic research strengths from different medical fields and employ professionals jointly with the collaborating hospitals to establish a supportive environment for advanced medical education. NSYSU has strong research teams and good reputation in material sciences, nano-technologies and electric/mechanical engineering. With the key techniques from different fields, NSYSU is now able to perform a cross-disciplinary study to translate scientific discoveries from biomedical research into real applicable products, which can provide more sensitive and accurate signals for clinical prognosis or patient management. It is expected that the traditional biomedical research combined with the cross-disciplinary technologies will make NSYSU a key player in the medical research both domestically and globally.
Facing the challenge of the novel coronavirus outbreaks, Professor Jim Jinn-Chyuan Sheu, Chair of the IBPS, pointed out that the novel coronavirus (COVID-19) is a newly defined virus that belongs to the Coronaviridae family. Similar to SARS-CoV and MERS-CoV, COVID-19 causes severe breathing difficulties in humans, which may be even lethal. In the near future, the IBPS will develop new antibody drugs, vaccines and novel phytochemicals against this devastating disease. At the same time, IBPS will cultivate professionals and researchers in the field of biopharmacy, finding new ways to treat severe diseases. Together with the faculty at Institute of Biomedical Sciences (IBMS), IBPS will conduct research on molecular mechanisms involved in viral infections and pathogenesis, providing strategies to block viral entry or to suppress virus replication in the infected cells. Through those studies, NSYSU will be able to establish a high throughput screening platform for new drug development against COVID-19.
According to the clinical statistics provided by the Chinese government and cited by Taiwan Centers for Disease Control, the median age of COVID-19-infected patients is about 49 years old and 73% of them are male. Professor Yow-Ling Shiue, Chair of the IPM, said that in the future, the Institute will do research to clarify the relationship between personal genomics and disease progression, and to understand why some infected patients show mild or even undetectable symptoms but some could be in very severe conditions. This study may help us to ensure no pitfalls in epidemic prevention. The IPM will cultivate interdisciplinary researchers with special focus on precision medicine to work on disease prediction, prevention and personalized treatments that can lead to biomedical innovation. By integrating the data of genetic signatures, lifestyles, environmental risk factors and health history, AI management and deep-learning technologies will enable us to design novel strategies in developing new diagnostic methods, drug delivery, systems and gene therapy for clinical practice.
In the future, these two institutes will integrate academic research strengths from different medical fields and employ professionals jointly with the collaborating hospitals to establish a supportive environment for advanced medical education. NSYSU has strong research teams and good reputation in material sciences, nano-technologies and electric/mechanical engineering. With the key techniques from different fields, NSYSU is now able to perform a cross-disciplinary study to translate scientific discoveries from biomedical research into real applicable products, which can provide more sensitive and accurate signals for clinical prognosis or patient management. It is expected that the traditional biomedical research combined with the cross-disciplinary technologies will make NSYSU a key player in the medical research both domestically and globally.
Click Num:
Share